Altered amino acid profile in patients with SARS-CoV-2 infection.
COVID-19
arginine
multisystem inflammatory syndrome in children
nitric oxide
tetrahydrobiopterin
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
22 06 2021
22 06 2021
Historique:
entrez:
5
6
2021
pubmed:
6
6
2021
medline:
16
6
2021
Statut:
ppublish
Résumé
Low plasma arginine bioavailability has been implicated in endothelial dysfunction and immune dysregulation. The role of arginine in COVID-19 is unknown, but could contribute to cellular damage if low. Our objective was to determine arginine bioavailability in adults and children with COVID-19 vs. healthy controls. We hypothesized that arginine bioavailability would be low in patients with COVID-19 and multisystem inflammatory syndrome in children (MIS-C). We conducted a prospective observational study of three patient cohorts; arginine bioavailability was determined in asymptomatic healthy controls, adults hospitalized with COVID-19, and hospitalized children/adolescents <21 y old with COVID-19, MIS-C, or asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection identified on admission screen. Mean patient plasma amino acids were compared to controls using the Student's
Identifiants
pubmed: 34088793
pii: 2101708118
doi: 10.1073/pnas.2101708118
pmc: PMC8237604
pii:
doi:
Substances chimiques
Amino Acids
0
Types de publication
Clinical Trial
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCCIH NIH HHS
ID : K24 AT009893
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104940
Pays : United States
Informations de copyright
Copyright © 2021 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
Competing interest statement: C.R.M. is the inventor or coinventor of several UCSF Benioff Children’s Hospital Oakland patents/patent-pending applications that include nutritional supplements, and biomarkers of cardiovascular disease related to arginine bioavailability; is an inventor of several Emory University School of Medicine patents/patent applications, including a patent filing for nutritional therapies that target coronaviruses; and is a consultant for Pfizer, Hoffmann-La Roche Ltd., and CSL Behring. M.B.V. is a consultant for Boehringer Ingelheim, Bristol Myers Squibb, Intercept, Eli Lilly, Novo Nordisk, and Target Pharmasolutions and has research funding from Bristol Myers Squibb and Target Pharmasolutions. J.B.O. has worked for Nestle Healthcare Nutrition, Inc.
Références
Int J Mol Sci. 2020 Nov 16;21(22):
pubmed: 33207699
Blood Adv. 2020 Dec 8;4(23):6051-6063
pubmed: 33290544
Eur J Psychiatry. 2021 Jan-Mar;35(1):62-63
pubmed: 33162632
J Clin Immunol. 2021 Apr;41(3):515-525
pubmed: 33387156
Immunol Rev. 2008 Apr;222:180-91
pubmed: 18364002
Biomedicines. 2020 Aug 06;8(8):
pubmed: 32781796
BMC Psychiatry. 2005 Jan 31;5:6
pubmed: 15683541
Int J Infect Dis. 2021 Jan;102:566-570
pubmed: 33160064
Am J Respir Crit Care Med. 2004 Jul 15;170(2):148-53
pubmed: 15070820
Blood. 2008 Jan 1;111(1):402-10
pubmed: 17848621
Front Pediatr. 2015 May 26;3:46
pubmed: 26075191
JAMA. 2005 Jul 6;294(1):81-90
pubmed: 15998894
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Nutr Clin Pract. 2017 Apr;32(1_suppl):30S-47S
pubmed: 28388380